ADC Control Human IgG1-Deruxtecan (DAR 8) provides a human IgG1-based control antibody-drug conjugate containing a deruxtecan (DXd) topoisomerase I inhibitor payload, while its defined drug-to-antibody ratio (DAR) of approximately 8 supports ADC assay development, payload evaluation, and comparative ADC research.
Key Features and Benefits
- Human IgG1 Control ADC: Provides an IgG1-based conjugate specifically for control and comparative studies in ADC research.
- Deruxtecan Payload: Contains a DXd topoisomerase I inhibitor payload specifically for studying ADC-mediated cytotoxic mechanisms.
- DAR 8: Provides a high drug-to-antibody ratio of approximately eight payload molecules per antibody for controlled comparative studies.
- Cleavable Linker-Payload: Supports intracellular release of the DXd payload following appropriate linker cleavage.
- Topoisomerase I Inhibition: DXd interferes with DNA replication through topoisomerase I inhibition, supporting cytotoxicity research.
- ADC Control Platform: Provides a useful comparator specifically for evaluating target-specific deruxtecan ADCs and experimental conjugates.
- Assay Development: Supports optimization of ADC cytotoxicity, stability, uptake, and cell-based assay conditions.
Applications
- ADC Control Studies: Provides a control conjugate for comparison with target-specific deruxtecan ADCs.
- ADC Assay Development: Supports development and optimization of biochemical and cell-based ADC assays.
- Deruxtecan Research: Useful for studying DXd payload activity and ADC-mediated cellular responses.
- DAR Studies: Supports investigation of how drug-to-antibody ratio influences ADC properties and experimental performance.
- Cytotoxicity Research: Useful for evaluating DXd-associated cellular effects and payload-dependent activity.
- Comparative ADC Research: Supports comparison of experimental ADCs with a Human IgG1-Deruxtecan control.
- Mechanism-of-Action Studies: Supports investigation of topoisomerase I inhibition and downstream cellular responses.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody and conjugate stability.
ADC Control Human IgG1-Deruxtecan (DAR 8) provides an IgG1-based control ADC with a DXd payload and defined high DAR and specifically supports ADC controls, cytotoxicity studies, DAR evaluation, and comparative deruxtecan ADC research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
